

Notice of Change to the Provider-Administered Drug Program

We are expanding the Provider-Administered Drug Program (PADP) drug list by adding biosimilar versions of already-included reference biologic products effective Oct. 1, 2018. Preservice reviews are now required for the biologics listed below prior to administration in the provider office, home, outpatient hospital, ambulatory surgical center, public health clinic and rural health clinic settings.

Drugs Affected by this Change

The chart below lists new drugs added to the program effective Oct. 1, 2018.

Procedure HCPCS	Drug Description	Reference Biologic
Q5106	Retacrit (epoestin alfa-epbx)	Epogen, Procrit
Q5108	Fulphila (pegfilgrastim-jmdb)	Neulasta

Process for Preservice Reviews

There is no change to the process for requesting a preservice medical necessity review for biosimilar drugs and other drugs in the PADP. Please contact Magellan Rx Management to request a preservice medical necessity through the secure Magellan Rx Management website at magellanrx.com or by calling Magellan Rx Management at 800-424-4947.

More Information

For a complete list of drugs included in the PADP, please refer to the *Provider-Administered Drug Program* section of the [Manual for Physicians and Providers](#) on our website at floridablue.com.